Revenue during the quarter grew 10.51 percent to $8.43 million from $7.63 million in the previous year period. Gross margin for the quarter expanded 1206 basis points over the previous year period to 56.20 percent.

Operating loss for the quarter was $18.09 million, compared with an operating loss of $15.34 million in the previous year period.

“Coming out of our first quarter, we remain optimistic about our growth prospects over the next several years from major markets including the U.S., France and South Africa, but were not able to sign new contracts for the latter two geographies by now as we had previously expected. Therefore, though no less confident in our ability to capture this new business in the near to medium term, we believe it is prudent to adjust our 2017 product revenue guidance to a new range of $43 to 48 million dollars,” said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “In the U.S., we are seeing increasing awareness regarding the FDA’s pending final guidance on bacterial safety, and are encouraged by the urgency currently being expressed by blood centers to meet hospital demand for INTERCEPT platelets.”